Biomarker Panel for Impaired Glucose Tolerance Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining glucose tolerance, such as the oral glucose tolerance test, require fasting and glucose administration, making them inconvenient and less desirable for widespread screening, particularly for identifying impaired glucose tolerance indicative of pre-diabetes or diabetes.
Innovation Solution
A method involving a biomarker panel comprising specific proteins like ACY1, COL1A1, RTN4R, CRLF1:CLCF1 complex, and others, detected using aptamer-based assays, to assess impaired glucose tolerance without the need for fasting or glucose administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional oral glucose tolerance test methods are used, then glucose tolerance can be determined, but the process requires fasting and glucose administration which reduces convenience and ease of operation
Solution Approach 1:
The invention extracts the essential diagnostic information from the complex OGTT process by identifying a specific panel of biomarkers (including ACY1, COL1A1, RTN4R, CRLF1:CLCF1 complex, and others) that can predict impaired glucose tolerance. This allows determination of glucose tolerance status through simple blood sampling without requiring fasting or glucose administration, thus removing the cumbersome procedural elements while retaining diagnostic accuracy
Solution Approach 2:
The invention changes the measurement parameters from direct glucose level monitoring (requiring OGTT) to measurement of multiple biomarker protein levels. By detecting the levels of specific proteins in the biomarker panel and analyzing their patterns, the system can infer glucose tolerance status, thereby transforming the diagnostic approach from a procedural test to a biomarker-based assessment that is more convenient for patients
2Reliability
If OGTT with fasting and glucose administration is performed, then impaired glucose tolerance can be identified, but the procedure complexity and time requirement increase
Solution Approach 1:
The invention performs preliminary identification of impaired glucose tolerance risk by measuring biomarker levels in a simple blood sample before any glucose challenge is administered. The biomarker panel analysis can predict which individuals are likely to have impaired glucose tolerance, allowing early identification and intervention before the development of full-blown diabetes, thus saving time by avoiding unnecessary OGTT procedures for at-risk individuals
3Measurement precision
If a biomarker panel with multiple proteins is used, then diagnostic accuracy improves, but the device complexity and analysis requirements increase
Solution Approach 1:
The invention employs a multi-functional detection system that can simultaneously measure multiple biomarker proteins (ACY1, COL1A1, RTN4R, CRLF1:CLCF1 complex, and others) using a single assay platform. This universal approach allows the same detection system to handle all biomarkers in the panel, reducing the need for multiple separate tests and simplifying the overall diagnostic process while maintaining high diagnostic accuracy through comprehensive biomarker analysis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the accurate identification of impaired glucose tolerance and pre-diabetes or diabetes risk, enabling early intervention and preventive measures without the constraints of traditional testing methods.
Implementation Method 1
detected using aptamer-based assays
Data Source
AI summary
Methods, compositions, and kits for determining whether a subject has impaired glucose tolerance, and more specifically pre-diabetes or diabetes, are provided.